Moderna Inc. (NASDAQ: MRNA) has announced today the results of the Phase 3 study of mRNA-1273. mRNA-1273 is the vaccine candidate of Moderna Inc. against COVID-19. The company dislcosed that its vaccine candidate has achieved 94.5% success in Phase III Study. The study